Search Results - "Debled, Marc"

Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.

Authors: Quenel-Tueux, Nathalie Debled, Marc Rudewicz, Justine et al.

Source: British Journal of Cancer. 8/11/2015, Vol. 113 Issue 4, p585-594. 10p.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.

Authors: Pivot, Xavier Romieu, Gilles Debled, Marc et al.

Source: Lancet. 6/29/2019, Vol. 393 Issue 10191, p2591-2598. 8p.

Subjects: Trastuzumab, Hormone receptor positive breast cancer, Breast cancer, Exposure therapy, Cancer chemotherapy, Ventricular ejection fraction

Geographic Terms: France

Subcutaneous auto-administration of trastuzumab following therapeutic education: A case report.

Authors: Deppenweiler, Marine Debled, Marc Robquin, Jean-Luc et al.

Source: Journal of Oncology Pharmacy Practice. Sep2019, Vol. 25 Issue 6, p1523-1525. 3p.

Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude.

Authors: Debled, Marc MacGrogan, Gaëtan Breton-Callu, Christelle et al.

Source: European Journal of Cancer. Apr2015, Vol. 51 Issue 6, p697-704. 8p.

Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision making.

Authors: Debled, Marc Auxepaules, Gaël de Lara, Christine Tunon et al.

Source: American Journal of Surgery. 2014, Vol. 208 Issue 5, p756-763. 8p.

First-line chemotherapy for metastatic breast cancer in patients ≥75 years: A retrospective single-centre analysis

Authors: Debled, Marc Madranges, Nicolas Mertens, Cécile et al.

Source: Critical Reviews in Oncology/Hematology. Oct2011, Vol. 80 Issue 1, p171-179. 9p.

Is It Useful to Detect Lymphovascular Invasion in Lymph Node-Positive Patients With Primary Operable Breast Cancer?

Authors: Ragage, Florence Debled, Marc MacGrogan, Gaëtan et al.

Source: Cancer (0008543X). 7/1/2010, Vol. 116 Issue 13, p3093-3101. 9p. 1 Diagram, 5 Charts, 2 Graphs.

First-Line Capecitabine Monotherapy for Slowly Progressing Metastatic Breast Cancer: Do We Need Aggressive Treatment?

Authors: Debled, Marc Madranges, Nicolas Trainaud, Alexandra et al.

Source: Oncology. 2009, Vol. 77 Issue 5, p318-327. 10p. 1 Diagram, 4 Charts, 4 Graphs.

Prognostic Factors of Early Distant Recurrence in Hormone Receptor-positive, Postmenopausal Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy.

Authors: Debled, Marc MacGrogan, Gaëtan Brouste, Véronique et al.

Source: Cancer (0008543X). Jun2007, Vol. 109 Issue 11, p2197-2204. 8p. 6 Charts.

Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer.

Authors: Bellera, Carine A. MacGrogan, Gaëtan Debled, Marc et al.

Source: BMC Medical Research Methodology. 2010, Vol. 10, p20-31. 12p.

A 21-Gene Expression Assay in Breast Cancer.

Authors: Debled, Marc Tunon de Lara, Christine MacGrogran, Gaëtan

Source: New England Journal of Medicine. 4/7/2016, Vol. 374 Issue 14, p1385-1386. 2p.

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.

Authors: François-Martin, Hélène Lardy-Cléaud, Audrey Pistilli, Barbara et al.

Source: Cancers. Feb2023, Vol. 15 Issue 4, p1191. 13p.

SHARED DECISION MAKING.

Authors: Debled, Marc Soum-Pouyalet, Fanny

Source: BMJ: British Medical Journal (Overseas & Retired Doctors Edition). 8/13/2011, Vol. 343 Issue 7819, p335-336. 2p.

Re: Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer.

Authors: DEBLED, MARC DE MASCAREL, ISABELLE BROUSTE, VERONIQUE et al.

Source: JNCI: Journal of the National Cancer Institute. 2/24/2010, Vol. 102 Issue 4, p275-276. 2p. 1 Graph.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Authors: Pivot, Xavier Romieu, Gilles Debled, Marc et al.

Source: Lancet Oncology. Jul2013, Vol. 14 Issue 8, p741-748. 8p.

Distinction Between Isolated Tumor Cells and Micrometastases in Breast Cancer.

Authors: de Mascarel, Isabelle MacGrogan, Gaetan Debled, Marc et al.

Source: Cancer (0008543X). 4/15/2008, Vol. 112 Issue 8, p1672-1678. 7p. 2 Diagrams, 5 Charts.

Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers.

Authors: Puccetti, Paolo Fallarino, Francesca Italiano, Antoine et al.

Source: PLoS ONE. Apr2015, Vol. 10 Issue 4, p1-9. 9p.

Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors.

Authors: Morgat, Clément MacGrogan, Gaétan Brouste, Véronique et al.

Source: Journal of Nuclear Medicine. Sep2017, Vol. 58 Issue 9, p1401-1407. 7p. 1 Color Photograph, 4 Charts, 1 Graph.

PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas.

Authors: Jones, Natalie Gros, Audrey Velasco, Valérie et al.

Source: Cancer Genetics. Jun2022, Vol. 264, p8-15. 8p.

Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.

Authors: Dalenc, Florence Lusque, Amélie De La Motte Rouge, Thibault et al.

Source: European Journal of Cancer. Mar2022, Vol. 164, p70-79. 10p.